Schoots Ivo G, Levi Marcel, van Vliet Arlène K, Declerck Paul J, Maas Adrie M, van Gulik Thomas M
Department of Surgery, Academic Medical Center, University of Amsterdam, The Netherlands.
Thromb Haemost. 2004 Mar;91(3):497-505. doi: 10.1160/TH03-08-0529.
This study investigated the contribution of endogenous suppression of fibrinolysis and increased fibrin deposition to intestinal dysfunction and injury in a rat model of intestinal ischemia/reperfusion (I/R), as fibrinolytic inhibition may lead to thrombotic obstructions that compromise microcirculation and promote intestinal injury. Circulatory fibrinolysis was enhanced by intravenous administration of recombinant tissue plasminogen activator (rt-PA) or by inhibition of PAI-I by administration of MA-33H1F7. Coagulation and fibrinolysis parameters obtained from portal blood were correlated to fibrin deposition (determined by anti-rat fibrin antibody staining), intestinal function (glucose/water clearance) and intestinal injury (histological evaluation by Park/Chiu score). Enhanced circulatory fibrinolytic activity, as evidenced by increased portal plasma plasminogen activator activity, elevated fibrin degradation products and decreased levels of PAI-I, did not reduce mucosal fibrin deposition and microthrombosis in postischemic intestinal tissue. Furthermore, rt-PA or anti-PAI-I antibody administration did not attenuate I/R-induced intestinal injury or dysfunction, as demonstrated by intestinal histopathology scores of 4.8+/-0.2 and 4.7+/-0.3 (control I/R group 4.7+/-0.2) and glucose clearances of 47+/-6 and 46+/-9 micro L/min g (control I/R group 30+/-8 micro L/min. g) after 40 minutes of intestinal ischemia and 3 hours of reperfusion, respectively. However, both interventions resulted in decreased levels of interleukin-6, which may indicate fibrin-induced modulation of inflammation. Attempts to enhance the fibrinolytic activity (either by rt-PA or by anti-PAI-I administration), indicated by increased portal plasma levels of released FDP, failed to decrease mucosal fibrin deposition and to attenuate intestinal I/R injury. Based on our observations and previous reports, the contribution of suppressed endogenous fibrinolysis to microcirculatory fibrin deposition and I/R-injury may be of limited importance.
本研究在大鼠肠缺血/再灌注(I/R)模型中,探讨了内源性纤维蛋白溶解抑制和纤维蛋白沉积增加对肠道功能障碍及损伤的作用,因为纤维蛋白溶解抑制可能导致血栓形成阻塞,损害微循环并促进肠道损伤。通过静脉注射重组组织型纤溶酶原激活剂(rt-PA)或给予MA-33H1F7抑制纤溶酶原激活物抑制剂-1(PAI-1)来增强循环纤维蛋白溶解。从门静脉血中获得的凝血和纤维蛋白溶解参数与纤维蛋白沉积(通过抗大鼠纤维蛋白抗体染色确定)、肠道功能(葡萄糖/水清除率)和肠道损伤(Park/Chiu评分组织学评估)相关。门静脉血浆纤溶酶原激活剂活性增加、纤维蛋白降解产物升高以及PAI-1水平降低所证明的循环纤维蛋白溶解活性增强,并未减少缺血后肠道组织中的黏膜纤维蛋白沉积和微血栓形成。此外,rt-PA或抗PAI-1抗体给药并未减轻I/R诱导的肠道损伤或功能障碍,分别在肠道缺血40分钟和再灌注3小时后,肠道组织病理学评分为4.8±0.2和4.7±0.3(对照I/R组为4.7±0.2),葡萄糖清除率为47±6和46±9微升/分钟·克(对照I/R组为30±8微升/分钟·克)。然而,两种干预均导致白细胞介素-6水平降低,这可能表明纤维蛋白诱导的炎症调节。通过增加门静脉血浆中释放的纤维蛋白降解产物(FDP)水平所表明的增强纤维蛋白溶解活性的尝试(通过rt-PA或抗PAI-1给药),未能减少黏膜纤维蛋白沉积并减轻肠道I/R损伤。基于我们的观察和先前的报道,内源性纤维蛋白溶解抑制对微循环纤维蛋白沉积和I/R损伤的作用可能有限。